The New England Comparative Effectiveness Public Advisory Council (CEPAC), a nationally recognized independent appraisal committee for ICER, found that adding tirzepatide to background therapy is superior to background therapy alone in a vote of 13 yes to 0 no
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Analysis And Forecast 2026 To 2035 Obesity Treatment Market Size and Growth Factors 2026 to 2035 The global obesity treatment market size reached USD 18.90 billion in 2025 and is expected to be worth around USD 112.87 billion by 2035, exhibiting at a compound annual growth rate (CAGR) of 19.57% over the forecast period 2026 to 2035
Also, dietary TMAO caused liver damage in mice [36]
The consequences and benefits for various parts of the economy now that we are seeing outcomes previously only consistent with bariatric surgery available in a pharmaceutical will be wide-reaching and important for investors to monitor
Graphical abstract In a meta-analysis of six observational studies, both SGLT2 inhibitors and GLP-1 receptor agonists were associated with a lower risk of venous thromboembolism compared with DPP-4 inhibitors, while no significant difference was observed between SGLT2 inhibitors and GLP-1 receptor agonists in head-to-head comparisons
